Bausch Health (BHC)
(Delayed Data from NYSE)
$8.88 USD
+0.17 (1.95%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $8.89 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BHC 8.88 +0.17(1.95%)
Will BHC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BHC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHC
All You Need to Know About Bausch (BHC) Rating Upgrade to Buy
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
BHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Other News for BHC
Piper Sandler Reaffirms Their Hold Rating on Bausch Health Companies (BHC)
Bausch Health price target raised by $2 at Piper Sandler, here's why
Bausch + Lomb reports positive study results for Blink NutriTears
FDA approves Amneal's generic version of OTC Narcan
Bausch Health price target lowered by $1 at RBC Capital, here's why